首页 > 产品中心 > 试剂盒 > ADA检测试剂盒

Enoblituzumab ELISA Kit (KPTX265)

价格:
规格:
数量:
  • 概述

  • 图片

  • 参考文献

概述
货号KPTX265
品牌ProteoGenix
描述
Enoblituzumab ELISA Kit (KPTX265) — Quantitative colorimetric ELISA. for Enoblituzumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL.
Highlights
  • High Sensitivity — Reliable quantification at low concentrations.
  • Ready-to-Use — Pre-coated plates for streamlined workflow.
样本类型Plasma, Serum
检测范围0.31-5 μg/mL
保存溶液 The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

检测方法Colorimetric
实验类型Quantitative
回收率80-120%
运输2-8 ℃
规格Enoblituzumab
别名MG-A271, , CAS: 1353485-38-7
背景Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.
NoteFor Research Use Only.
图片
参考文献
公式
质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)
填写 质量、浓度、体积中的任意 2 项 + 分子量,自动计算未知值。
质量
=
浓度
×
体积
分子量 *
g/mol
公式
C₁ × V₁ = C₂ × V₂
填写 4 项中的任意 3 项,自动计算未知值。
母液
C₁ (起始浓度)
×
V₁ (起始体积)
=
工作液
C₂ (终浓度)
×
V₂ (终体积)

相关产品推荐